Small molecule drug companies develop low-molecular-weight medicines designed to interact with specific biological targets. These compounds can often enter cells and may be formulated as oral or other conventional dosage forms across a wide range of therapeutic areas.
This category includes companies working on:
Browse 221 UK small molecule drug companies below.
Specialist pharma acquiring and developing rare disease therapeutics
Ambrose Healthcare is a UK specialist pharmaceutical company developing treatments for rare diseases and patients in hospital and specialist care settings. The company builds its pipeline through the acquisition and licensing of late-stage clinical assets with existing human safety and efficacy data, targeting…
Oral small molecule therapies for rare hereditary diseases
KalVista Pharmaceuticals is a biopharmaceutical company specialising in the discovery and commercialisation of oral small molecule protease inhibitors for rare diseases with significant unmet need. The company's lead programme targets the kallikrein-kinin system and has produced an approved oral on-demand therapy for…
Global biopharma focused on severe neurological and immunological diseases
UCB Pharma is the UK subsidiary of UCB S.A., a Belgian biopharmaceutical company focused on the discovery and development of treatments for severe neurological and immunological diseases. The UK operation is one of UCB's three global R&D hubs, with capabilities spanning antibody discovery, small molecule development,…
Mitochondrial disease drug discovery subsidiary of Astellas Pharma
Astellas Engineered Small Molecules U.K. is a Cambridge-based drug discovery subsidiary of Astellas Pharma, operating as part of the company's Mitobridge Division alongside its US counterpart Mitobridge Inc. Originally founded as Nanna Therapeutics and acquired by Astellas in 2020, the entity applies a proprietary…
Global specialist pharmaceutical company focused on HIV
ViiV Healthcare is a specialist pharmaceutical company dedicated to the research, development, and commercialisation of medicines for HIV treatment and prevention. Its portfolio includes widely used antiretroviral therapies such as Dovato and the long-acting injectable Cabenuva, and it is advancing next-generation…
Clinical-stage biotech developing treatments for multiple myeloma
CellCentric is a clinical-stage biopharmaceutical company developing inobrodib, a first-in-class oral inhibitor of the p300/CBP transcription co-activation proteins, for relapsed and refractory multiple myeloma. Inobrodib has been evaluated in over 400 patients and holds FDA Fast Track and orphan drug designations.…
AI platform for drug target identification and discovery
BenevolentAI is a UK-founded biotech company that develops and applies AI and machine learning to accelerate drug discovery. Its platform integrates knowledge graphs, proprietary ontologies, and large language models to identify novel therapeutic targets and design small molecule candidates across multiple disease…
API development and GMP manufacturing for pharmaceutical innovators
Dr. Reddy's Laboratories is the UK manufacturing and contract services subsidiary of Indian multinational Dr. Reddy's Laboratories. Operating as Custom Pharma Services (CPS), the company provides contract development and GMP manufacturing of active pharmaceutical ingredients, intermediates and finished dosage forms…
Small molecule therapeutics targeting lipid-signalling pathways
Artelo Biosciences is a clinical-stage biopharmaceutical company developing small molecule therapeutics that modulate lipid-signalling pathways, including the endocannabinoid system. Its pipeline includes ART27.13, a peripherally selective cannabinoid receptor agonist in Phase 2 for cancer-associated anorexia and…
Precision small molecule drugs for obsessive-compulsive disorder
Serenatis Bio is a preclinical-stage biotech developing small molecule drugs to treat obsessive-compulsive disorder (OCD). Its pipeline of three candidates targets distinct neurological mechanisms, including glutamate, AMPA, and dopamine pathways, with a biomarker-driven approach designed to match patients to…
Quantum-informed computational design of covalent drug candidates
Axiom Therapeutics is a London biotechnology company using molecular physics and machine learning to design covalent small-molecule medicines. Its computational drug-discovery platform models interactions between reactive compounds and biological targets, helping design selective inhibitors for difficult-to-drug…
Integrated drug discovery services for biotech and pharma
BioAscent is a Scotland-based integrated drug discovery contract research organisation providing science-led services to biotech, pharmaceutical, and academic customers. Operating from the former MSD R&D site in Newhouse, its capabilities span assay development, high-throughput screening, medicinal and synthetic…
Computational chemistry and data informatics for drug discovery
NovaData Solutions is a contract research organisation providing computational chemistry, molecular modelling, and data informatics services to pharmaceutical and biotechnology clients. Its capabilities span the early drug discovery workflow, including target validation, hit identification, lead optimisation, and…
Small molecule therapeutics targeting astrocytes in Parkinson's disease
Cellestial Health is a pre-clinical stage biotechnology company and University of Cambridge spinout developing small molecule therapeutics for Parkinson's disease and other neurodegenerative conditions. The company's approach targets astrocytic networks, a class of brain cells whose dysregulation contributes to…
Generic and branded prescription medicines development and supply
Northumbria Pharma is a pharmaceutical company specialising in the development, manufacture, licensing, and supply of generic and branded prescription medicines across primary and secondary care. Its portfolio spans multiple therapeutic areas including rare diseases, neurology, respiratory, and oncology supportive…
Phase 1 clinical research and bioanalytical services for drug development
Celerion is a contract research organisation specialising in early-stage clinical research for pharmaceutical and biotechnology clients. Operating from a dedicated Phase 1 clinic in Belfast, the company conducts first-in-human studies, bioequivalence and bioavailability trials, cardiac safety studies, and ADME…
Cambridge R&D hub for GPCR-based drug discovery
Nxera Pharma UK is the Cambridge-based drug discovery arm of Tokyo-listed Nxera Pharma, formerly Sosei Heptares, operating from Granta Park with approximately 170 scientists. Its structure-based drug discovery capabilities have produced over 50 resolved GPCR structures. Following a restructuring in November 2025, the…
Not-for-profit research organisation targeting intrinsically disordered proteins
Bind Research is the UK's first Focused Research Organisation, established to make intrinsically disordered proteins druggable targets for new medicines. The organisation integrates NMR spectroscopy, biophysical characterisation, chemoproteomics, and AI to build comprehensive datasets of disordered protein-small…
AI-powered molecular design software for medicinal chemists
deepmirror is a software company developing an AI-powered drug design application for medicinal chemists. Its no-code interface integrates generative molecular design with predictive modelling of key drug properties including target affinity, ADMET profiles and solubility, enabling hit-to-lead and lead optimisation…
Fragment-based drug discovery platform for oncology and CNS disorders
Astex Pharmaceuticals is a drug discovery and development company pioneering fragment-based drug discovery through its proprietary Pyramid platform, applied to oncology and central nervous system disorders. Astex maintains an internal pipeline alongside active collaborations with MSD targeting KRAS and p53. The…